Patents by Inventor M. Amin Khan

M. Amin Khan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20230312591
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: November 14, 2022
    Publication date: October 5, 2023
    Inventor: M. Amin Khan
  • SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME
    Publication number: 20230210851
    Abstract: Disclosed are spiro-lactam compounds, and pharmaceutically acceptable salts thereof, that can ameliorate or treat a viral infection in a subject in need thereof. The disclosure also includes conjugates of such compounds of viral protease inhibitors with the cysteine at position or an equivalent active site cysteine on the coronavirus main protease (Mpro).
    Type: Application
    Filed: June 3, 2021
    Publication date: July 6, 2023
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME
    Publication number: 20230192693
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: July 28, 2022
    Publication date: June 22, 2023
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20230131402
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: June 3, 2022
    Publication date: April 27, 2023
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME
    Publication number: 20230128006
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: June 3, 2022
    Publication date: April 27, 2023
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11578072
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 14, 2023
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11530223
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: December 20, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11512051
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: November 29, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA modulators and methods of using same
    Patent number: 11427585
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: August 30, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20220220119
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 13, 2021
    Publication date: July 14, 2022
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11376250
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: July 5, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA modulators and methods of using same
    Patent number: 11370790
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: June 28, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20220151992
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: June 24, 2021
    Publication date: May 19, 2022
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11299495
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: April 12, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20220098211
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: May 7, 2021
    Publication date: March 31, 2022
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20220002242
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: February 17, 2021
    Publication date: January 6, 2022
    Inventor: M. Amin Khan
  • NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20210332061
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: December 4, 2020
    Publication date: October 28, 2021
    Inventors: M. Amin Khan, Joseph R. Moskal, Paul Wood
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20210322406
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: December 1, 2020
    Publication date: October 21, 2021
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11077094
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: August 3, 2021
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • PROCESS FOR SYNTHESIS OF PEPTIDE COMPOUNDS
    Publication number: 20210198315
    Abstract: Disclosed is a new process for preparing dipyrrolidine peptide compounds such as, for example, GLYX-13. Advantageously, the process may be industrially scalable and cost-effective and use less toxic reagents and/or solvents. Further, the process may be used to prepare peptide compounds having improved purity.
    Type: Application
    Filed: January 31, 2017
    Publication date: July 1, 2021
    Applicant: Naurex, Inc
    Inventor: M. Amin KHAN